Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $1.74M | — | — | $70.0K | — | — |
| Operating income | -$13.8M | -$13.8M | -$713K | -$4.31M | -$7.58M | -$9.13M | -$9.72M | -$6.65M | -$3.58M | -$3.19M |
| Operating margin | — | — | — | — | -435.7% | — | — | -9497.2% | — | — |
| Net income | -$13.7M | -$13.8M | -$713K | -$6.64M | -$9.50M | -$9.39M | $5.09M | -$7.90M | -$4.52M | $249M |
| Net margin | — | — | — | — | -545.9% | — | — | -11290.1% | — | — |
| EPS (diluted) | -$0.51 | -$0.52 | -$0.12 | -$0.11 | -$0.11 | -$0.03 | $0.01 | -$0.02 | -$0.01 | $0.59 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.2M | -$10.9M | -$241K | -$2.28M | -$2.81M | -$4.43M | -$1.45M | -$1.32M | -$740K | -$1.38M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.54M | $1.11M | $2.50K | $82.0K | $474K | $569K | $241K | $170K | — | — |
| Total assets | $14.1M | $1.17M | $2.75M | $23.7M | $23.7M | $23.6M | $36.1M | $30.0M | $26.7M | $393M |
| Total liabilities | — | — | — | — | — | — | $16.9M | $18.4M | $19.2M | $131M |
| Shareholders' equity | $12.5M | -$484K | $2.46M | $16.9M | $11.8M | $7.96M | $19.4M | $12.1M | $8.25M | $263M |
| Retained earnings | -$278M | -$292M | -$5.49M | -$12.1M | -$21.6M | -$31.0M | -$25.9M | -$33.5M | -$38.0M | $211M |
| Shares (wtd avg diluted) | 26.5M | 26.5M | 6.84M | 84.1M | 88.1M | 303M | 457M | 396M | 404M | 422M |
Every figure is extracted from Oncotelic Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.